Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes cytotoxic agents, docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiological response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kYcnQv
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Sexual dimorphism in the human respiratory system has been previously reported at the skeletal (cranial and thoracic) level, but ...
-
We are excited to share with you the newest dentistry and patient safety editions recently added to STAT!Ref. As a reminder, all STAT!Ref c...
-
Abstract The effects of oxygen addition on a helium-based flowing atmospheric pressure afterglow (FAPA) ionization source are explored. Sm...
-
Objective Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. Ho...
-
2016-12-10T02-17-59Z Source: Indo American Journal of Pharmaceutical Research M.R. Pradeep Kumar*, Shrinivas D. Joshi . With an objecti...
-
Chemotherapy has been shown to enrich cancer stem cells in tumors. Recently, we demonstrated that administration of chemotherapy to human bl...
-
Related Articles Corrections. Otolaryngol Head Neck Surg. 2007 Dec;137(6):987 Authors: PMID: 29135374 [PubMed] from #AlexandrosS...
-
http://ift.tt/2svTdo9
-
The evaluation of mineral resources development efficiency is a typical multicriteria decision-making issue. Meanwhile, due to the limited e...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου